ZA200500467B - Novel aryl-{4-halo-4-[(heteroarylmethylamino)methyl]-piperidin-1-yl}methanone derivatives methods for production and use thereof as medicaments - Google Patents
Novel aryl-{4-halo-4-[(heteroarylmethylamino)methyl]-piperidin-1-yl}methanone derivatives methods for production and use thereof as medicaments Download PDFInfo
- Publication number
- ZA200500467B ZA200500467B ZA2005/00467A ZA200500467A ZA200500467B ZA 200500467 B ZA200500467 B ZA 200500467B ZA 2005/00467 A ZA2005/00467 A ZA 2005/00467A ZA 200500467 A ZA200500467 A ZA 200500467A ZA 200500467 B ZA200500467 B ZA 200500467B
- Authority
- ZA
- South Africa
- Prior art keywords
- piperidin
- methanone
- methyl
- fluoro
- amino
- Prior art date
Links
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 title claims description 13
- 239000003814 drug Substances 0.000 title claims description 9
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- 238000000034 method Methods 0.000 title description 12
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 21
- 229910052731 fluorine Inorganic materials 0.000 claims abstract description 20
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 5
- 239000011707 mineral Substances 0.000 claims abstract description 5
- 150000007524 organic acids Chemical class 0.000 claims abstract description 5
- 235000005985 organic acids Nutrition 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 67
- -1 3-chloro-4-fluorophenyl Chemical group 0.000 claims description 35
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 18
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims description 16
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 15
- 125000001153 fluoro group Chemical group F* 0.000 claims description 13
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 11
- 239000000460 chlorine Substances 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 150000004677 hydrates Chemical class 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 3
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 3
- 239000011737 fluorine Substances 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 2
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims description 2
- 150000003254 radicals Chemical class 0.000 claims description 2
- SALDQMKGRXMXGW-UHFFFAOYSA-N (3-chloro-4-fluorophenyl)-[4-[[(5-chloropyridin-2-yl)methylamino]methyl]-4-fluoropiperidin-1-yl]methanone Chemical compound C1=C(Cl)C(F)=CC=C1C(=O)N1CCC(F)(CNCC=2N=CC(Cl)=CC=2)CC1 SALDQMKGRXMXGW-UHFFFAOYSA-N 0.000 claims 1
- XPMHHHJWQFUFAU-UHFFFAOYSA-N (3-chloro-4-fluorophenyl)-[4-fluoro-4-[[[5-(fluoromethyl)pyridin-2-yl]methylamino]methyl]piperidin-1-yl]methanone Chemical compound N1=CC(CF)=CC=C1CNCC1(F)CCN(C(=O)C=2C=C(Cl)C(F)=CC=2)CC1 XPMHHHJWQFUFAU-UHFFFAOYSA-N 0.000 claims 1
- CKPPJYLPMTUPAS-UHFFFAOYSA-N 2-fluoro-5-[4-fluoro-4-[[(5-methylpyridin-2-yl)methylamino]methyl]piperidine-1-carbonyl]benzonitrile Chemical compound N1=CC(C)=CC=C1CNCC1(F)CCN(C(=O)C=2C=C(C(F)=CC=2)C#N)CC1 CKPPJYLPMTUPAS-UHFFFAOYSA-N 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 150000007522 mineralic acids Chemical class 0.000 abstract description 2
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 abstract 1
- 150000003053 piperidines Chemical class 0.000 abstract 1
- 150000001299 aldehydes Chemical class 0.000 description 29
- 238000002360 preparation method Methods 0.000 description 20
- 150000003141 primary amines Chemical class 0.000 description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- 238000005481 NMR spectroscopy Methods 0.000 description 16
- 239000000243 solution Substances 0.000 description 14
- 239000000556 agonist Substances 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 10
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- SARODJOLCPBJHK-UHFFFAOYSA-N 5-methylpyridine-2-carbaldehyde Chemical compound CC1=CC=C(C=O)N=C1 SARODJOLCPBJHK-UHFFFAOYSA-N 0.000 description 5
- ASXGJMSKWNBENU-UHFFFAOYSA-N 8-OH-DPAT Chemical compound C1=CC(O)=C2CC(N(CCC)CCC)CCC2=C1 ASXGJMSKWNBENU-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- LLZMRNQIAVJCJO-UHFFFAOYSA-N ethyl 6-(methoxymethoxymethyl)pyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC=C(COCOC)N=C1 LLZMRNQIAVJCJO-UHFFFAOYSA-N 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- FQTYMPNTUHMTSE-UHFFFAOYSA-N 5-(fluoromethyl)-2-(methoxymethoxymethyl)pyridine Chemical compound COCOCC1=CC=C(CF)C=N1 FQTYMPNTUHMTSE-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- BIJPUEBJPVFNFK-UHFFFAOYSA-N [5-(fluoromethyl)pyridin-2-yl]methanol Chemical compound OCC1=CC=C(CF)C=N1 BIJPUEBJPVFNFK-UHFFFAOYSA-N 0.000 description 4
- XIWLINXCINBRDK-UHFFFAOYSA-N [6-(methoxymethoxymethyl)pyridin-3-yl]methanol Chemical compound COCOCC1=CC=C(CO)C=N1 XIWLINXCINBRDK-UHFFFAOYSA-N 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- GVORVQPNNSASDM-UHFFFAOYSA-N 3-chloro-4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1Cl GVORVQPNNSASDM-UHFFFAOYSA-N 0.000 description 3
- OBPDHHJZPOGJPO-UHFFFAOYSA-N 5-methylpyrimidine-2-carbaldehyde Chemical compound CC1=CN=C(C=O)N=C1 OBPDHHJZPOGJPO-UHFFFAOYSA-N 0.000 description 3
- OPKGSXZJDAALJL-UHFFFAOYSA-N 6-methylpyridazine-3-carbaldehyde Chemical compound CC1=CC=C(C=O)N=N1 OPKGSXZJDAALJL-UHFFFAOYSA-N 0.000 description 3
- 208000020401 Depressive disease Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- GRJJQCWNZGRKAU-UHFFFAOYSA-N pyridin-1-ium;fluoride Chemical compound F.C1=CC=NC=C1 GRJJQCWNZGRKAU-UHFFFAOYSA-N 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- AJEWINCTRQUEBR-UHFFFAOYSA-N (3,4-dichlorophenyl)-[4-fluoro-4-[[(6-methylpyridazin-3-yl)methylamino]methyl]piperidin-1-yl]methanone Chemical compound N1=NC(C)=CC=C1CNCC1(F)CCN(C(=O)C=2C=C(Cl)C(Cl)=CC=2)CC1 AJEWINCTRQUEBR-UHFFFAOYSA-N 0.000 description 2
- NVTWGZZOUHDHMJ-UHFFFAOYSA-N (3-chloro-4-fluorophenyl)-[4-chloro-4-[[(5-methylpyridin-2-yl)methylamino]methyl]piperidin-1-yl]methanone Chemical compound N1=CC(C)=CC=C1CNCC1(Cl)CCN(C(=O)C=2C=C(Cl)C(F)=CC=2)CC1 NVTWGZZOUHDHMJ-UHFFFAOYSA-N 0.000 description 2
- FYZMKBCVXADJDJ-UHFFFAOYSA-N (4-amino-4-fluoro-2-methylpiperidin-1-yl)-(3,4-dichlorophenyl)methanone Chemical compound CC1CC(N)(F)CCN1C(=O)C1=CC=C(Cl)C(Cl)=C1 FYZMKBCVXADJDJ-UHFFFAOYSA-N 0.000 description 2
- XXDCLDJEBGLWOD-UHFFFAOYSA-N 5-(fluoromethyl)pyridine-2-carbaldehyde Chemical compound FCC1=CC=C(C=O)N=C1 XXDCLDJEBGLWOD-UHFFFAOYSA-N 0.000 description 2
- UEEOOYQIXPMRQP-UHFFFAOYSA-N 6-[[[1-(3-chloro-4-fluorobenzoyl)-4-fluoropiperidin-4-yl]methylamino]methyl]pyridine-3-carbonitrile Chemical compound C1=C(Cl)C(F)=CC=C1C(=O)N1CCC(F)(CNCC=2N=CC(=CC=2)C#N)CC1 UEEOOYQIXPMRQP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- QFNPKPKDVHIBAU-UHFFFAOYSA-N [4-fluoro-4-[[(5-methylpyridin-2-yl)methylamino]methyl]piperidin-1-yl]-(4-fluorophenyl)methanone Chemical compound N1=CC(C)=CC=C1CNCC1(F)CCN(C(=O)C=2C=CC(F)=CC=2)CC1 QFNPKPKDVHIBAU-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- RDSGPHNFOMPILP-UHFFFAOYSA-N ethyl 6-(hydroxymethyl)pyridine-3-carboxylate Chemical compound CCOC(=O)C1=CC=C(CO)N=C1 RDSGPHNFOMPILP-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- NSPJNIDYTSSIIY-UHFFFAOYSA-N methoxy(methoxymethoxy)methane Chemical compound COCOCOC NSPJNIDYTSSIIY-UHFFFAOYSA-N 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- 230000002295 serotoninergic effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- UFXIRMVZNARBDL-UHFFFAOYSA-N trifluoro(morpholin-4-yl)-$l^{4}-sulfane Chemical compound FS(F)(F)N1CCOCC1 UFXIRMVZNARBDL-UHFFFAOYSA-N 0.000 description 2
- ZOHLVMOSQKCSQF-UHFFFAOYSA-N (4-amino-4-chloro-2-methylpiperidin-1-yl)-(3-chloro-4-fluorophenyl)methanone Chemical compound NC1(CC(N(CC1)C(=O)C1=CC(=C(C=C1)F)Cl)C)Cl ZOHLVMOSQKCSQF-UHFFFAOYSA-N 0.000 description 1
- NYGPGBNGJWOLSH-UHFFFAOYSA-N (4-amino-4-fluoro-2-methylpiperidin-1-yl)-(4-chloro-3-fluorophenyl)methanone Chemical compound CC1CC(N)(F)CCN1C(=O)C1=CC=C(Cl)C(F)=C1 NYGPGBNGJWOLSH-UHFFFAOYSA-N 0.000 description 1
- JHUJYGKCJLKHDD-UHFFFAOYSA-N (4-amino-4-fluoro-2-methylpiperidin-1-yl)-[3-(trifluoromethyl)phenyl]methanone Chemical compound NC1(CC(N(CC1)C(=O)C1=CC(=CC=C1)C(F)(F)F)C)F JHUJYGKCJLKHDD-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- WOXFMYVTSLAQMO-UHFFFAOYSA-N 2-Pyridinemethanamine Chemical compound NCC1=CC=CC=N1 WOXFMYVTSLAQMO-UHFFFAOYSA-N 0.000 description 1
- JMHGATOBRPWPBZ-UHFFFAOYSA-N 3-cyano-4-fluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C(C#N)=C1 JMHGATOBRPWPBZ-UHFFFAOYSA-N 0.000 description 1
- UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 description 1
- BHYFALILZZJFPL-UHFFFAOYSA-N 5-(4-amino-4-fluoro-2-methylpiperidine-1-carbonyl)-2-fluorobenzonitrile Chemical compound CC1CC(N)(F)CCN1C(=O)C1=CC=C(F)C(C#N)=C1 BHYFALILZZJFPL-UHFFFAOYSA-N 0.000 description 1
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 1
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 1
- DMDMMMFMXWZSLM-UHFFFAOYSA-N 6-formylpyridine-3-carbonitrile Chemical compound O=CC1=CC=C(C#N)C=N1 DMDMMMFMXWZSLM-UHFFFAOYSA-N 0.000 description 1
- MBVKWGKPRADLAP-UHFFFAOYSA-N 6-methylpyridazine-3-carbonitrile Chemical compound CC1=CC=C(C#N)N=N1 MBVKWGKPRADLAP-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 101100383807 Mus musculus Chpf gene Proteins 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 1
- 208000036366 Sensation of pressure Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001559 benzoic acids Chemical class 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229940061627 chloromethyl methyl ether Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical class C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229960001779 pargyline Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 150000003138 primary alcohols Chemical group 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- CEIJFEGBUDEYSX-FZDBZEDMSA-N tandospirone Chemical compound O=C([C@@H]1[C@H]2CC[C@H](C2)[C@@H]1C1=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 CEIJFEGBUDEYSX-FZDBZEDMSA-N 0.000 description 1
- 229950000505 tandospirone Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0207470A FR2840900B1 (fr) | 2002-06-18 | 2002-06-18 | Nouveaux derives d'aryl[4-halogeno-4- [(heteroaryl-methylamino)-methyl]-piperidin-1-yl]-methanone, leur procede de preparation et leur utilisation a titre de medicaments |
| PCT/FR2003/001873 WO2003106449A1 (fr) | 2002-06-18 | 2003-06-18 | Nouveaux derives d'aryl-{4-halogeno-4-[heteroaryl-methylamino)-methyl]-piperidin-1-yl}-methanone, leur procede de preparation et leur utilisation a titre de medicaments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200500467B true ZA200500467B (en) | 2005-12-28 |
Family
ID=29595331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2005/00467A ZA200500467B (en) | 2002-06-18 | 2005-01-18 | Novel aryl-{4-halo-4-[(heteroarylmethylamino)methyl]-piperidin-1-yl}methanone derivatives methods for production and use thereof as medicaments |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7547700B2 (enExample) |
| EP (1) | EP1539738B1 (enExample) |
| JP (1) | JP4699027B2 (enExample) |
| CN (1) | CN1308325C (enExample) |
| AT (1) | ATE424396T1 (enExample) |
| AU (1) | AU2003258816B2 (enExample) |
| BR (1) | BRPI0311976B8 (enExample) |
| CA (1) | CA2489723C (enExample) |
| DE (1) | DE60326468D1 (enExample) |
| ES (1) | ES2321927T3 (enExample) |
| FR (1) | FR2840900B1 (enExample) |
| MX (1) | MXPA05000024A (enExample) |
| WO (1) | WO2003106449A1 (enExample) |
| ZA (1) | ZA200500467B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2852244B1 (fr) | 2003-03-13 | 2007-09-07 | Pf Medicament | Utilisation de derives de pyridin-2-yl-methylamine pour la preparation d'un medicament destine au traitement des symptomes de la douleur chronique d'origine neuropathique ou psychogene |
| FR2891274B1 (fr) * | 2005-09-27 | 2007-11-23 | Pierre Fabre Medicament Sa | Procede de preparation du (3-chloro-4-fluoro-phenyl)-(4- fluoro-4-{[(5-methyl-pyrimidin-2-ylmethyl)-amino]-methyl}- piperidin-1-yl)-methanone et nouveaux derives pyrimidiniques intermediaires. |
| US8389534B2 (en) * | 2008-05-19 | 2013-03-05 | The University Of Tennessee Research Foundation | Pyrimidine non-classical cannabinoid compounds and related methods of use |
| CA2724737A1 (en) * | 2008-05-19 | 2009-11-26 | The University Of Tennessee Research Foundation | Pyrimidine non-classical cannabinoid compounds and related methods of use |
| FR2946344B1 (fr) | 2009-06-05 | 2012-05-25 | Pf Medicament | Nouveaux derives d'aryl-{4-halogeno-4-[aminomethyl]-piperidin-1-yl} methanone, leur procede de preparation et leur utilisation a titre de medicaments |
| EP2338873A1 (en) | 2009-12-22 | 2011-06-29 | Gmeiner, Peter | New aminotetraline derivatives |
| WO2018057576A1 (en) * | 2016-09-22 | 2018-03-29 | Auspex Pharmaceuticals, Inc. | Deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds |
| US11191758B2 (en) | 2017-07-20 | 2021-12-07 | Neurolixis | Use of selective serotonin 5-HT1A receptor agonists for treating side-effects of VMAT inhibitors |
| WO2023144166A1 (en) | 2022-01-26 | 2023-08-03 | Neurolixis | Use of serotonin 5-ht1a receptor agonists to treat diseases associated with sudden unexpected death in epilepsy |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN169588B (enExample) * | 1986-10-07 | 1991-11-16 | Pfizer Hospital Prod | |
| FR2755967B1 (fr) * | 1996-11-21 | 1999-01-29 | Pf Medicament | Derives de la pyridin-2-yl-methylamine, leur procede de preparation et leur application comme medicaments |
| FR2784378B1 (fr) * | 1998-10-09 | 2000-12-29 | Pf Medicament | Nouveaux derives d'aryl-(4-fluoro-4-[(2-pyridin-2-yl- ethylamino)-methyl]-piperidin-1-yl)-methanone, leur procede de preparation et leur utilisation a titre de medicaments |
| FR2820743B1 (fr) * | 2001-02-09 | 2005-02-25 | Pf Medicament | Procede et intermediaires de synthese pour la preparation de derives de pyridin-2-yl-methylamine |
-
2002
- 2002-06-18 FR FR0207470A patent/FR2840900B1/fr not_active Expired - Lifetime
-
2003
- 2003-06-18 CA CA2489723A patent/CA2489723C/fr not_active Expired - Lifetime
- 2003-06-18 MX MXPA05000024A patent/MXPA05000024A/es active IP Right Grant
- 2003-06-18 US US10/518,394 patent/US7547700B2/en active Active
- 2003-06-18 AU AU2003258816A patent/AU2003258816B2/en not_active Expired
- 2003-06-18 CN CNB038186047A patent/CN1308325C/zh not_active Expired - Lifetime
- 2003-06-18 DE DE60326468T patent/DE60326468D1/de not_active Expired - Lifetime
- 2003-06-18 BR BRPI0311976A patent/BRPI0311976B8/pt not_active IP Right Cessation
- 2003-06-18 ES ES03760060T patent/ES2321927T3/es not_active Expired - Lifetime
- 2003-06-18 EP EP03760060A patent/EP1539738B1/fr not_active Expired - Lifetime
- 2003-06-18 WO PCT/FR2003/001873 patent/WO2003106449A1/fr not_active Ceased
- 2003-06-18 AT AT03760060T patent/ATE424396T1/de not_active IP Right Cessation
- 2003-06-18 JP JP2004513281A patent/JP4699027B2/ja not_active Expired - Lifetime
-
2005
- 2005-01-18 ZA ZA2005/00467A patent/ZA200500467B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2489723A1 (fr) | 2003-12-24 |
| HK1075452A1 (en) | 2005-12-16 |
| DE60326468D1 (de) | 2009-04-16 |
| JP4699027B2 (ja) | 2011-06-08 |
| ES2321927T3 (es) | 2009-06-15 |
| BRPI0311976B1 (pt) | 2015-08-18 |
| EP1539738B1 (fr) | 2009-03-04 |
| AU2003258816A1 (en) | 2003-12-31 |
| BR0311976A (pt) | 2005-03-29 |
| AU2003258816B2 (en) | 2008-08-21 |
| US7547700B2 (en) | 2009-06-16 |
| WO2003106449A1 (fr) | 2003-12-24 |
| CA2489723C (fr) | 2011-08-02 |
| CN1308325C (zh) | 2007-04-04 |
| EP1539738A1 (fr) | 2005-06-15 |
| US20060100244A1 (en) | 2006-05-11 |
| BRPI0311976B8 (pt) | 2021-05-25 |
| ATE424396T1 (de) | 2009-03-15 |
| CN1675194A (zh) | 2005-09-28 |
| WO2003106449A8 (fr) | 2005-02-17 |
| FR2840900A1 (fr) | 2003-12-19 |
| JP2005534668A (ja) | 2005-11-17 |
| FR2840900B1 (fr) | 2005-02-25 |
| MXPA05000024A (es) | 2005-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR0149649B1 (ko) | 2-(1-피페라진일)-4-페닐시클로알카노피리딘 유도체, 그들의 제조방법 및 그들을 함유하는 약학적 조성물 | |
| RU2165933C2 (ru) | Производные пиперазина, способ их получения, фармацевтическая композиция и способ лечения синдрома 8-oh-dpat | |
| TW200403224A (en) | Novel compounds | |
| WO1997047601A1 (en) | Fused heterocyclic compounds and medicinal uses thereof | |
| JPH054983A (ja) | イソキノリノン誘導体、その製造方法およびその誘導体を有効成分として含有する５−ｈｔ３ レセプター拮抗剤 | |
| JP2010535742A (ja) | オルメサルタンメドキソミルの調製または精製の方法 | |
| US4885302A (en) | 2-((4-Piperidyl)methyl)-1,2,3,4-tetrahydroisoquinoline derivatives, their preparation and their application in therapy | |
| NO860319L (no) | Fremgangsmaate for fremstillig av terapeutisk aktive 4h-1-benzopyran-4-on-derivater og deres svovelholdige analoger. | |
| JPH0523269B2 (enExample) | ||
| ZA200500467B (en) | Novel aryl-{4-halo-4-[(heteroarylmethylamino)methyl]-piperidin-1-yl}methanone derivatives methods for production and use thereof as medicaments | |
| AU2021410119A1 (en) | Tetrahydroquinoline derivative and medicinal use thereof | |
| JPH01168677A (ja) | 向精神性非環式アミド誘導体 | |
| US20040034036A1 (en) | N-(3,5-dichloro-2-methoxyphenyl)-4-methoxy-3-piperazin-1-yl-benzenesulfonamide | |
| IE59201B1 (en) | Pyridinylpiperazine derivatives | |
| KR102700883B1 (ko) | 3-(5-플루오로벤조푸란-3-일)-4-(5-메틸-5H-[1,3]디옥솔로[4,5-f]인돌-7-일)피롤-2,5-디온의 고체 형태 | |
| KR20050119673A (ko) | 크로메논 인돌 | |
| JPH0733744A (ja) | インダゾール誘導体およびその塩 | |
| PT1458703E (pt) | Compostos isocromano para o tratamento de perturbações do snc | |
| AU761122B2 (en) | Aryl-(4-flouro-4-((2-pyridin-2-yl-ethylamino)-methyl)- piperidin-1-yl)-methanone derivatives as 5-HT1 receptor antagonists | |
| HU184059B (en) | Process for preparing new 1,2-benzothiazine-1,1-dioxyde derivatives and pharmaceutical sompositions containing such compounds | |
| HK1075452B (en) | Novel aryl- 4-halo-4- heteroarylmethylamino)-methyl -piperidin-1-yl -methanone derivatives, methods for production and use thereof as medicaments | |
| JPH0827149A (ja) | ピリミジノン誘導体およびその塩 | |
| WO2000018763A2 (en) | 2-(2,3-dihydrobenzofuran-5-yl)-4-aminomethylimidazoles: dopamine receptor subtype specific ligands | |
| JP2016106072A (ja) | プロペラン誘導体 | |
| MXPA01003586A (en) | Aryl-{4-fluoro-4- [(2-pyridin-2-yl- ethylamino)-methyl]- piperidin-1- yl}-methanone derivatives as 5-ht1 receptor antagonists |